Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'GANIRELIX' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 18 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Diedrich, K; Ludwig, M; Felberbaum, RE
      The role of gonadotropin-releasing hormone antagonists in in vitro fertilization

      SEMINARS IN REPRODUCTIVE MEDICINE
    2. De Jong, D; Van Hooren, EG; Macklon, NS; Mannaerts, BMJL; Fauser, BCJM
      Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI, using aGnRH antagonist (orgalutran/antagon) to prevent a premature LH surge: A case report

      JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
    3. van Hooren, HG
      Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LHsurges in women undergoing ovarian stimulation

      HUMAN REPRODUCTION
    4. Elter, K; Nelson, LR
      Use of third generation gonadotropin-releasing hormone antagonists in in vitro fertilization-embryo transfer: A review

      OBSTETRICAL & GYNECOLOGICAL SURVEY
    5. de Jong, D; Macklon, NS; Eijkemans, MJC; Mannaerts, BMJL; Bennink, HJTC; Fauser, BCJM
      Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon)

      FERTILITY AND STERILITY
    6. Erb, K; Klipping, C; Duijkers, I; Pechstein, B; Schueler, A; Hermann, R
      Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women

      FERTILITY AND STERILITY
    7. Fluker, M; Grifo, J; Leader, A; Levy, M; Meldrum, D; Muasher, SJ; Rinehart, J; Rosenwaks, Z; Scott, RT; Schoolcraft, W; Shapiro, DB
      Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

      FERTILITY AND STERILITY
    8. Borm, G; Mannaerts, B
      Treatment with the gonadotrophin-releasing hormone antagonist ganirelix inwomen undergoing ovarian stimulation with recombinant follicle stimulatinghormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial

      HUMAN REPRODUCTION
    9. Oberye, J; Mannaerts, B; Huisman, J; Timmer, C
      Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran (R)) administration by Medi-Jector (R) compared to conventional needle injections

      HUMAN REPRODUCTION
    10. Demirel, LC; Weiss, JM; Polack, S; Unlu, C; Diedrich, K; Ortmann, O
      Effect of the gonadotropin-releasing hormone antagonist ganirelix on cyclic adenosine monophosphate accumulation of human granulosa-lutein cells

      FERTILITY AND STERILITY
    11. Gillies, PS; Faulds, D; Balfour, JAB; Perry, CM
      Ganirelix

      DRUGS
    12. Erb, K; Pechstein, B; Schueler, A; Engel, J; Hermann, R
      Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men -a first-dose-in-humans study

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    13. Kol, S; Lightman, A; Hillensjo, T; Devroey, P; Fauser, B; Tarlatzis, B; Mannaerts, B; Itskovitz-Eldor, J
      High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles

      HUMAN REPRODUCTION
    14. Oberye, JJL; Mannaerts, BMJL; Kleijn, HJ; Timmer, CJ
      Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran*). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers

      FERTILITY AND STERILITY
    15. Oberye, JJL; Mannaerts, BMJL; Huisman, JAM; Timmer, CJ
      Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran*). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers

      FERTILITY AND STERILITY
    16. ITSKOVITZELDOR J; KOL S; MANNAERTS B; BENNINK HC
      FIRST ESTABLISHED PREGNANCY AFTER CONTROLLED OVARIAN HYPERSTIMULATIONWITH RECOMBINANT FOLLICLE-STIMULATING-HORMONE AND THE GONADOTROPIN-RELEASING-HORMONE ANTAGONIST GANIRELIX (ORG-37462)

      Human reproduction
    17. MANNAERTS B; DEVROEY P; ABYHOLM T; DIEDRICH K; HILLENSJO T; HEDON B; ITSKOVITZELDOR J; KAHN J; NAETHER O; OLIVENNES F; PAVLOU S; TARLATZIS B; WESTERGAARD L; VANDERHEIJDEN B; COELINGH H
      A DOUBLE-BLIND, RANDOMIZED, DOSE-FINDING STUDY TO ASSESS THE EFFICACYOF THE GONADOTROPIN-RELEASING-HORMONE ANTAGONIST GANIRELIX (ORG-37462) TO PREVENT PREMATURE LUTEINIZING-HORMONE SURGES IN WOMEN UNDERGOING OVARIAN STIMULATION WITH RECOMBINANT FOLLICLE-STIMULATING-HORMONE (PUREGON((R)))

      Human reproduction (Oxford. Print)
    18. NELSON LR; FUJIMOTO VY; JAFFE RB; MONROE SE
      SUPPRESSION OF FOLLICULAR PHASE PITUITARY-GONADAL FUNCTION BY A POTENT NEW GONADOTROPIN-RELEASING-HORMONE ANTAGONIST WITH REDUCED HISTAMINE-RELEASING PROPERTIES (GANIRELIX)

      Fertility and sterility


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/08/20 alle ore 02:27:11